Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | GSR | P00390 | 2/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890552 | 1.00 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL890462 | 0.86 | PTGS1 (0.39) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL890461 | 0.86 | PTGS1 (0.39) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL5371555 | 0.83 | THRB (0.40) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL11243408 | 0.82 | GRB2 (0.40) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL18774923 | 0.81 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL15962510 | 0.81 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL3905797 | 0.80 | NOS2 (0.40) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL4533762 | 0.80 | PTGS1 (0.46) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL2627414 | 0.80 | PTGS1 (0.46) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171500-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250092094-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240238369-A1 | Conformationally Specific Viral Immunogens | CALDER BIOSCIENCES INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11926649-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-03-12 | — | — | US | disclosed |
| US-11752191-B2 | Conformationally-specific viral immunogens | CALDER BIOSCIENCES INC (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230053714-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | ALIA THERAPEUTICS SRL (IT) | 2023-02-23 | — | — | US | disclosed |
| EP-4077674-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | Alia Therapeutics S.R.L. (IT) | 2022-10-26 | — | — | EP | disclosed |
| US-11267848-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC. | 2022-03-08 | — | — | US | disclosed |
| US-20210322512-A1 | CONFORMATIONALLY-SPECIFIC VIRAL IMMUNOGENS | CALDER BIOSCIENCES INC (US) | 2021-10-21 | — | — | US | disclosed |
| EP-1641813-A4 | METHODS FOR OBTAINING MOLECULES WITH REDUCED IMMUNOGENICITY | AVATAR BIOTECHNOLOGIES INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7037894-B2 | Stabilized proteins | AVATAR MEDICAL, LLC (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1641813-A2 | METHODS FOR OBTAINING MOLECULES WITH REDUCED IMMUNOGENICITY | Avatar Biotechnologies, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005051975-A2 | METHODS FOR OBTAINING MOLECULES WITH REDUCED IMMUNOGENICITY | AVATAR BIOTECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050123530-A1 | Stabilized proteins | AVATAR MEDICAL, LLC (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050054572-A1 | Methods for obtaining molecules with reduced immunogenicity | CALDER BIOSCIENCES INC. | 2005-03-10 | — | — | US | disclosed |
| EP-1282722-A4 | STABILIZED PROTEINS | AVATAR MEDICAL L L C (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1282722-A1 | STABILIZED PROTEINS | Avatar Medical, L.L.C. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020061549-A1 | Stabilized proteins | CALDER BIOSCIENCES INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001029247-A1 | STABILIZED PROTEINS | AVATAR MEDICAL, LLC (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | RHOC, PDE6C, PDE6H | PTGS1 1969/4885SLC7A11 4322/4885SLC1A1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.